|Day Low/High||8.78 / 8.99|
|52 Wk Low/High||3.61 / 9.78|
This biopharma company's Relistor drug should send revenues sharply higher next year.
Study to Enroll 300 Patients in U.S. and Canada
What's in, what's out and who should thrive in the new political landscape.
The worst appears to be over for this sector; we could see big growth ahead.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AHP, ARCX, ATNI, HTGC, MGM, PGNX, PGRE, SGMS, SYF, WABC Downgrades: ABDC, ARCC, ARII, BOJA, CTLT, FSM, GEL, H, KMPR, LBTYA, LBTYB, LBTYK, TSCO Initiations: PEN, PSTG Read on to get TheStreet Quant Ratings' detailed report:
Provides Non-Dilutive Funding to Advance Late-Stage Oncology Portfolio
These small-caps are woefully undervalued after getting shellacked in October.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors considering a purchase of Progenics Pharmaceuticals, Inc. stock, but tentative about paying the going market price of $5.67/share, might benefit from considering selling puts among the alternative strategies at their disposal.
This sector is one of the few areas of the market where you'll find myriad compelling values.
BioDelivery Sciences, Progenics Pharma and Sequential Brands are off-the-radar small-caps poised for a big year in 2017.
RELISTOR Tablets FDA-Approved for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain
The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 930,934 share increase in total short interest for Progenics Pharmaceuticals, Inc. , to 10,136,448, an increase of 10.11% since 07/29/2016.
Biotech stocks dominate our list of top charts today. Here are four to watch.
Company Eligible to Receive Up to $200 Million of Sales Milestone Payments and Ongoing Sales Royalties
Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.